Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
BRL-201 by BRL Medicine for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia): Likelihood of Approval
BRL-201 is under clinical development by BRL Medicine and currently in Phase I for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute...
BRL-201 by BRL Medicine for Primary Mediastinal B-Cell Lymphoma: Likelihood of Approval
BRL-201 is under clinical development by BRL Medicine and currently in Phase I for Primary Mediastinal B-Cell Lymphoma. According to...
BRL-201 by BRL Medicine for Follicular Lymphoma: Likelihood of Approval
BRL-201 is under clinical development by BRL Medicine and currently in Phase I for Follicular Lymphoma. According to GlobalData, Phase...
BRL-201 by BRL Medicine for Mantle Cell Lymphoma: Likelihood of Approval
BRL-201 is under clinical development by BRL Medicine and currently in Phase I for Mantle Cell Lymphoma. According to GlobalData,...
BRL-201 by BRL Medicine for Diffuse Large B-Cell Lymphoma: Likelihood of Approval
BRL-201 is under clinical development by BRL Medicine and currently in Phase I for Diffuse Large B-Cell Lymphoma. According to...
BRL-201 by BRL Medicine for B-Cell Non-Hodgkin Lymphoma: Likelihood of Approval
BRL-201 is under clinical development by BRL Medicine and currently in Phase I for B-Cell Non-Hodgkin Lymphoma. According to GlobalData,...